Warning: foreach() argument must be of type array|object, bool given in /var/www/html/web/app/themes/studypress-core-theme/template-parts/header/mobile-offcanvas.php on line 20

An unapproved form of gene therapy, known as enhancement gene therapy, can create considerable ethical dilemmas. Why?

Short Answer

Expert verified
Answer: The main ethical dilemmas associated with enhancement gene therapy include concerns about safety, unequal access to treatment, individual autonomy and consent, potential for abuse and misuse, and the impact on human identity and dignity. These dilemmas arise because enhancement gene therapy, which aims to improve non-medical characteristics or abilities, is often unapproved and not thoroughly researched or regulated, leading to potential negative consequences on individual and societal levels.

Step by step solution

01

Introduction to enhancement gene therapy

Enhancement gene therapy refers to the use of genetic modification techniques to improve or augment certain characteristics or abilities in an individual that are not related to treating or curing diseases or medical conditions. This form of therapy is often unapproved and not authorized for medical use due to many ethical concerns.
02

Ethical concerns about safety

One of the main ethical issues surrounding enhancement gene therapy is its safety. As it is an unapproved form of therapy, thorough research and testing may not be conducted, potentially leading to negative side effects or health problems for individuals who undergo the treatment. Without rigorous testing and oversight, there is a risk of harm to patients, which raises ethical concerns about the potential consequences of such therapies.
03

Unequal access to treatment

Another ethical concern regarding enhancement gene therapy is the potential for unequal access to these treatments. Since these therapies may be expensive and not covered by health insurance, only a small portion of the population may be able to afford them. This could lead to an unfair distribution of enhanced abilities, advantages, and opportunities, creating social inequality and further widening the gap between the rich and the poor.
04

Ethical concerns about individual autonomy and consent

A critical ethical issue concerning enhancement gene therapy is the potential for infringement on individual autonomy and consent. These treatments often involve irreversible changes to an individual's genetic makeup. Parents may decide to undergo these procedures for their children without consent or input from the child, raising ethical questions about the right to control one's own body and life.
05

Potential for abuse and misuse

There is also an ethical concern about the potential for abuse and misuse of enhancement gene therapy. Some individuals or organizations may be tempted to use these therapies for nefarious purposes or to unfairly compete against others in areas such as sports, academics, or employment. This raises moral questions about the possible consequences of gene enhancement on an individual and societal level.
06

Impact on human identity and dignity

Lastly, enhancement gene therapy can fuel ethical debates about the impact on human identity and dignity. The idea of "designer babies," where parents could potentially select desired traits and abilities for their children, challenges common beliefs about human nature and raises questions about the ethical implications of creating "enhanced" humans. In conclusion, enhancement gene therapy presents various ethical dilemmas due to concerns about safety, unequal access, individual autonomy and consent, the potential for abuse, and the impact on human identity and dignity. Without proper regulations and careful consideration of the ethical implications, this form of therapy could lead to negative consequences on both individual and societal levels.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with Vaia!

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

In March 2010 Judge \(R\). Sweet ruled to invalidate Myriad Genetics' patents on the \(B R C A 1\) and \(B R C A 2\) genes. Sweet wrote that since the genes are part of the natural world, they are not patentable. Myriad Genetics also holds patents on the development of a direct-to-consumer test for the \(B R C A 1\) and \(B R C A 2\) genes. (a) Would you agree with Judge Sweet's ruling to invalidate the patenting of the \(B R C A 1\) and \(B R C A 2\) genes? If you were asked to judge the patenting of the direct-to-consumer test for the BRCA1 and BRCA2 genes, how would you rule? (b) J. Craig Venter has filed a patent application for his "firstever human made life form." This patent is designed to cover the genome of \(M\). genitalium. Would your ruling for Venter's "organism" be different from Judge Sweet's ruling on patenting of the \(B R C A 1\) and \(B R C A 2\) genes?

Sequencing the human genome and the development of microarray technology promise to improve our understanding of normal and abnormal cell behavior. How are microarrays dramatically changing our understanding of complex diseases such as cancer?

In this chapter, we focused on a number of interesting applications of genetic engineering, genomics, and biotechnology. At the same time, we found many opportunities to consider the methods and reasoning by which much of this information was acquired. From the explanations given in the chapter, what answers would you propose to the following fundamental questions: (a) What experimental evidence confirms that we have introduced a useful gene into a transgenic organism and that it performs as we anticipate? (b) How can we use DNA analysis to determine that a human fetus has sickle- cell anemia? (c) How can DNA microarray analysis be used to identify specific genes that are being expressed in a specific tissue? (d) How are GWAS carried out, and what information do they provide? (e) What are some of the technical reasons why gene therapy is difficult to carry out effectively?

The first attempts at gene therapy began in 1990 with the treatment of a young girl with a genetic disorder abbreviated SCID. What does SCID stand for? In the context of SCID, what does ADA stand for?

What limits the use of differences in restriction enzyme sites as a way of detecting point mutations in human genes?

See all solutions

Recommended explanations on Biology Textbooks

View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.

Sign-up for free